Recent Finacing
Recent Raise
CorriXR develops a patented non-viral CRISPR gene-editing platform that disables NRF2 to sensitize solid tumors—targeting squamous cell carcinomas (head, neck, lung)—for monotherapy, neoadjuvant, or combination use.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at CorriXR Therapeutics.
